Edwards Lifesciences (XSWX:EW) Cyclically Adjusted Revenue per Share: CHF6.93 (As of Mar. 2026)


XSWX:EW Edwards Lifesciences Corp XSWX:EW
97 GF Score
Price CHF72.91
GF Value CHF75.73
! 5 Warning Signs
View Full Analysis

What is Edwards Lifesciences Cyclically Adjusted Revenue per Share?

Edwards Lifesciences XSWX:EW +0.37% 97 Cyclically Adjusted Revenue per Share is CHF6.93 as of Mar. 2026. GuruFocus rates XSWX:EW with a GF Score™ of 97/100 and a GF Value™ of CHF75.73. The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Edwards Lifesciences's adjusted revenue per share for the three months ended in Mar. 2026 was CHF2.235. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is CHF6.93 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Edwards Lifesciences's average Cyclically Adjusted Revenue Growth Rate was 10.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 9.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 11.80% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 13.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Edwards Lifesciences was 15.20% per year. The lowest was 8.60% per year. And the median was 12.15% per year.

As of today (2026-06-26), Edwards Lifesciences's current stock price is CHF72.91. Edwards Lifesciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was CHF6.93. Edwards Lifesciences's Cyclically Adjusted PS Ratio of today is 10.52.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Edwards Lifesciences was 23.68. The lowest was 8.13. And the median was 13.23.


Edwards Lifesciences  (XSWX:EW) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Edwards Lifesciences's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=72.91/6.93
=10.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Edwards Lifesciences was 23.68. The lowest was 8.13. And the median was 13.23.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Edwards Lifesciences Cyclically Adjusted Revenue per Share Related Terms


Edwards Lifesciences Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Edwards Lifesciences's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Edwards Lifesciences Cyclically Adjusted Revenue per Share Chart

Edwards Lifesciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Edwards Lifesciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 6.93

XSWX:EW vs DXCM, GEHC, BSX: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Edwards Lifesciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Edwards Lifesciences Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Edwards Lifesciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Edwards Lifesciences's Cyclically Adjusted PS Ratio falls into.


XSWX:EW
97GF Score
Edwards Lifesciences Corp XSWX:EW
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Edwards Lifesciences Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Edwards Lifesciences's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=2.235/330.2130*330.2130
=2.235

Current CPI (Mar. 2026) = 330.2130.

Edwards Lifesciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 1.129 241.018 1.547
201609 1.100 241.428 1.505
201612 1.196 241.432 1.636
201703 1.363 243.801 1.846
201706 1.259 244.955 1.697
201709 1.219 246.819 1.631
201712 1.358 246.524 1.819
201803 1.315 249.554 1.740
201806 1.455 251.989 1.907
201809 1.373 252.439 1.796
201812 1.523 251.233 2.002
201903 1.561 254.202 2.028
201906 1.688 256.143 2.176
201909 1.703 256.759 2.190
201912 1.809 256.974 2.325
202003 1.705 258.115 2.181
202006 1.419 257.797 1.818
202009 1.654 260.280 2.098
202012 1.651 260.474 2.093
202103 1.792 264.877 2.234
202106 1.983 271.696 2.410
202109 1.914 274.310 2.304
202112 1.938 278.802 2.295
202203 1.980 287.504 2.274
202206 2.127 296.311 2.370
202209 2.056 296.808 2.287
202212 0.650 296.797 0.723
202303 2.211 301.836 2.419
202306 1.911 305.109 2.068
202309 1.835 307.789 1.969
202312 1.804 306.746 1.942
202403 1.956 312.332 2.068
202406 2.025 314.175 2.128
202409 1.918 315.301 2.009
202412 2.092 315.605 2.189
202503 2.124 319.799 2.193
202506 2.119 322.561 2.169
202509 2.111 324.800 2.146
202512 2.151 324.054 2.192
202603 2.235 330.213 2.235

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of CHF6.93 mean?
Edwards Lifesciences (XSWX:EW) has a Cyclically Adjusted Revenue per Share of CHF6.93 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Edwards Lifesciences and its competitors.
Is Edwards Lifesciences' Cyclically Adjusted Revenue per Share too high?
Edwards Lifesciences' current Cyclically Adjusted Revenue per Share is CHF6.93. Overall, Edwards Lifesciences has a GF Score™ of 97/100, reflecting its overall financial health beyond just this single metric.
How does Edwards Lifesciences' Cyclically Adjusted Revenue per Share compare to DXCM and GEHC?
Edwards Lifesciences' Cyclically Adjusted Revenue per Share of CHF6.93 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Edwards Lifesciences and its competitors. Edwards Lifesciences's current Cyclically Adjusted Revenue per Share is CHF6.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edwards Lifesciences stock overvalued right now?
Edwards Lifesciences (XSWX:EW) has a current Cyclically Adjusted Revenue per Share of CHF6.93. The stock's GF Value™ is CHF75.73, compared to a current price of CHF72.91 — trading 3.7% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is CHF6.93. Edwards Lifesciences' overall GF Score™ is 97/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Edwards Lifesciences (XSWX:EW), the current Cyclically Adjusted Revenue per Share is CHF6.93 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Edwards Lifesciences (XSWX:EW) Overvalued in 2026?

Based on GuruFocus' analysis, Edwards Lifesciences stock appears to be undervalued. The current stock price of CHF72.91 is trading 3.7% below its estimated GF Value™ of CHF75.73.

Key valuation signals for XSWX:EW:

  • Cyclically Adjusted Revenue per Share: CHF6.93
  • GF Value™: CHF75.73 vs. price of CHF72.91 (3.7% below fair value)
  • GF Score™: 97/100 with 5 warning signs

No single metric tells the full story. See the XSWX:EW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Edwards Lifesciences Business Description

Address One Edwards Way, Irvine, CA, USA, 92614
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
97GF Score

Get the complete analysis for XSWX:EW

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF72.91
Price
CHF75.73
GF Value